CS2013 / CStone Pharma - LARVOL DELTA

Expanding into Autoimmunity & Inflammation | CStone Unveils Two Novel Bispecific Antibody Targets for Autoimmune/Inflammatory Diseases (CStone Pharma Press Release) - "CStone...announced the first disclosure of the targets for two internally developed bispecific antibodies, aiming to address autoimmune/inflammatory diseases: CS2013 (B-cell-Activating Factor [BAFF]/ A Proliferation-Inducing Ligand [APRIL]); CS2015 (OX40 Ligand [OX40L]/ Thymic Stromal Lymphopoietin [TSLP])...Both have best-in-class (BIC)/first-in-class (FIC) potential and have advanced to the preclinical candidate (PCC) nomination stage, preclinical data will be disclosed at international academic conferences. In addition, the Investigational New Drug (IND)-enabling studies are expected to commence in H2 2025...CS2013 targets B-cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), IgA nephropathy (IgAN)...CS2015, a potential FIC bispecific antibody....provides a strategic approach for type 2 inflammatory diseases including atopic dermatitis (AD), asthma, etc."

Pipeline update • Preclinical • Asthma • Atopic Dermatitis • IgA Nephropathy • Inflammation • Rheumatoid Arthritis • Systemic Lupus Erythematosus